Closed the second round of funding worth $60 million in CoMind, a British start-up specialising in neurotechnology. With this investment, Angelini Ventures confirms its commitment to CoMind, after co-leading alongside Octopus Venture. the previous funding, in 2023, and confirms interest in innovation related to brain health monitoring.
This second round, led by Plural, with participation from LocalGlobe and Angelini Ventures, brings CoMind’s total funding to $102.5 million.
The aim of the funding is to support CoMind in completing the authorisation process for CoMind One, the first device capable of continuously and non-invasively monitoring cerebral blood flow, cerebral pressure and other critical physiological parameters with a single measurement.
CoMind One technology will overcome the challenges faced by doctors treating critically ill patients when monitoring brain activity. For decades, they have had to choose between risky, costly and highly invasive procedures, or relying on non-invasive but inaccurate monitoring, which can compromise treatment decisions.
CoMind One uses a low-power laser to transmit light through the scalp and skull to the brain tissue. The reflected signal is then combined with a second laser beam, creating an interference pattern that is highly sensitive to the state of the brain.
The device is the first capable of simultaneously measuring three key indicators of brain health: cerebral blood flow, cerebral autoregulation, and intracranial pressure.
This technology also allows the detection of brain oxygenation levels, brain metabolism and other critical physiological parameters, all without the need for surgery.
Thanks to its ability to provide essential information about patients’ brain health in a simple and continuous manner, CoMind One will help doctors make life-saving decisions.
“This second investment confirms the confidence we had placed in CoMind’s visionary team from the outset. What began as a gamble on a bold idea is now turning into a real opportunity to revolutionise brain monitoring with a real impact on patients,” said Elia Stupka, managing director who led the investment, in a statement. For Angelini Ventures, promoting brain health is a strategic priority, and CoMind is the perfect complement to our portfolio of companies active in biotech and drug discovery, offering a revolutionary medtech solution that will have a real impact on millions of patients.
“The brain is our most important organ, but monitoring the brains of hospitalised patients is totally inadequate and archaic,” says James Dacombe, founder and CEO of CoMind (pictured). “CoMind products aim to provide doctors with more information about the state of the brain to improve patient safety and treatment outcomes.”
By acquiring comprehensive neurological data through a single sensor, CoMind’s technology provides the hardware foundation to power future artificial intelligence tools capable of analysing patterns, predicting complications, and guiding treatment decisions in real time.
With the closing of the investment, Plural partner Taavet Hinrikus joins CoMind’s board of directors alongside experienced healthcare executives Michael Tarnoff, MD, former CEO of Tufts Medical Centre and Chief Medical Officer of MedTronic, and board chair Frank Fischer, a veteran of the medical device industry and president of Neuropace.
“ This technology is set to revolutionise the standard of care for patients requiring brain monitoring,” adds Michael Tarnoff, member of the CoMind board of directors. “Thanks to the device’s ability to provide non-invasive, continuous access to cerebral blood flow, cerebral autoregulation and intracranial pressure, the company will contribute to a new and important understanding of the complex physiology affecting these critically ill patients. This will lead to significant results in terms of risk reduction and improved clinical outcomes, as well as cost savings.”
This technology can be applied annually to millions of patients in intensive care, surgery, and other neurocritical settings, with the prospect of being adopted across the continuum of care.
The new funding will support the regulatory approval process for CoMind One in the United States, the completion of additional clinical trials, team expansion, and manufacturing partnerships.
ALL RIGHTS RESERVED ©